Hassane SADOU YAYÉ

Dr. Hassane SADOU YAYÉ

Pitié-Salpêtrière Hospital, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
TOTHIRION Olivier
THIRION Olivier
HYHassane SADOU YAYÉ
Hassane SADOU YAYÉ
TDThibaud Damy
Thibaud Damy
AAAlain Astier
Alain Astier
BDBernard Do
Bernard Do
Because of its antioxidant, antimutagenic, and anti-infectious properties, epigallocatechin gallate (EGCG) is the most interesting compound among the green tea catechins polyphenols. However, its health effects are inconclusive due to its very low bioavailability, largely due to a particular instability that does not allow EGCG to reach the potency required for clinical developments. Over the last decade, many efforts have been made to improve the stability and bioavailability of EGCG using complex delivery systems such as nanotechnology, but these efforts have not been successful and easy to translate to industrial use. To meet the needs of a large-scale clinical trial requiring EGCG in a concentrated solution to anticipate swallowing impairments, we developed an EGCG-based aqueous solution in the simplest way while trying to circumvent EGCG instability. The solution was thoroughly characterized to sort out the unexpected stability outcome by combining experimental (HPLC-UV-mass spectrometry and infrared spectroscopy) and computational (density functional theory) studies. Against all odds, the EGCG–sucrose complex under certain conditions may have prevented EGCG from degradation in aqueous media. Indeed, in agreement with the ICH guidelines, the formulated solution was shown to be stable up to at least 24 months under 2–8 °C and at ambient temperature. Furthermore, considerable improvement in bioavailability in rats, against EGCG powder formulated in hard-gel capsules, was shown after gavage. Thus, the proposed formulation may provide an easily implementable platform to administer EGCG in the context of clinical development.

1 March 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
HYHassane SADOU YAYÉ
Hassane SADOU YAYÉ
ASAudrey Solgadi
Audrey Solgadi
MAMarie Antignac
Marie Antignac
LTLionel Tortolano
Lionel Tortolano
BDBernard Do
Bernard Do

17 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
MAMaxime Annereau
Maxime Annereau
WKWilly Kini-Matondo
Willy Kini-Matondo
BPBastien Prost
Bastien Prost
JPJade Prudhomme
Jade Prudhomme
BDBernard Do
Bernard Do
Nirmatrelvir is an antiviral drug approved for the treatment of COVID-19. The available dosage form consists of tablets marketed under the brand name PAXLOVID®. Although knowledge of nirmatrelvir’s intrinsic stability may be useful for any potential development of other pharmaceutical forms, no data regarding this matter is available to date. Preliminary forced degradation studies have shown that the molecule is stable under oxidative and photolytic conditions, while hydrolytic conditions, both acidic and basic, have proven deleterious. Indeed, the molecule presents a priori several functions that can undergo hydrolysis, i.e., three amide moieties and a nitrile function. However, considering the degradation products formed under forced conditions and which were detected and identified by LC-UV-HRMSn, the hydrolysis process leading to their formation is selective since it involved only 2 of the 4 hydrolysable functions of the molecule. Ab initio studies based on density functional theory (DFT) have helped better understand these reactivity differences in aqueous media. Some hydrolyzable functions of nirmatrelvir differ from others in terms of electrostatic potential and Fukui functions, and this seems to correlate with the forced degradation outcomes.

1 January 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
HYHassane SADOU YAYÉ
Hassane SADOU YAYÉ
LHLamia Hassani
Lamia Hassani
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
MBMartine Babiard
Martine Babiard
HAHaroun Aouati
Haroun Aouati
IRIvo B. Rietveld
Ivo B. Rietveld

1 September 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HYHassane SADOU YAYÉ
Hassane SADOU YAYÉ
Ivo Boudewijn RietveldIvo Boudewijn Rietveld
Ivo Boudewijn Rietveld
MBMaria Barrio
Maria Barrio
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
AFAntoine Faucheron
Antoine Faucheron
BDBernard Do
Bernard Do
The mainstay treatment for patients with acute coronary syndrome is an oral route dual antiplatelet therapy with a P2Y12-receptor antagonist and Aspirin (ASA). To improve patient adherence to such treatments, combination therapies (polypill) are envisioned. Physicochemical solid-state studies have been carried out to develop a preformulation strategy of ASA with the P2Y12-receptor antagonist Ticagrelor (TIC). The investigations were carried out using differential scanning calorimetry, liquid chromatography-high resolution-multistage mass spectrometry (LC-HR-MSn) and as complementary techniques Fourier transform infrared measurements and thermogravimetric analysis. A simple eutectic transition at 98°C with a mole fraction for the eutectic liquid of 0.457 has been observed and the mixing of ASA and TIC molecules in each other's crystal structures appears to be limited. No cocrystals of TIC and ASA have been found. The appearance of the eutectic liquid was linked with a clear onset of chemical instability of the two pharmaceuticals. The decomposition mechanism in the liquid phase involves prior decomposition of ASA, whose residues react with well-identified TIC interaction sites. Seven interaction products were observed by LC-HR-MSn linked to corresponding degradation products. The most important degradation pathway is N-dealkylation. In conclusion, polypills of ASA and TIC are a viable approach, but the decomposition of ASA should be avoided by eliminating high temperatures and high humidity.

1 April 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
JSJoel Schlatter
Joel Schlatter
Salvatore CisterninoSalvatore Cisternino
Salvatore Cisternino
MAMarie Antignac
Marie Antignac
TOTHIRION Olivier
THIRION Olivier
BDBernard Do
Bernard Do